Clinical Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, placebo-controlled phase 1/2 clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HS-10561 capsule in healthy Chinese adults and patients with chronic spontaneous urticaria.
Trial Details
NCT Number NCT06864507
Lead Sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions Chronic Spontaneous Urticaria
Enrollment 150 participants
Start Date 2025-03-31
Primary Completion 2026-09-27 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-07